Sarcopenia risk along the cardiovascular-kidney-metabolic syndrome spectrum: synergistic effects of multisystem burden and physical inactivity Authors: Dingding Wang, Meng Zhang, Qinghua Fan, Jianwen Yu, Jianbo Li, Lanping Jiang, Xunhua Zheng, Siyang Ye, Suchun Li, Peichen Xie, Li Tan, Sixiu Chen, Weixuan Qin, Leigang Jin, Xiaoping Wu, Sydney CW Tang, Yifeng Luo, Wei Chen, Bin Li Published: 2025 ABSTRACT AbstractBackgroundSarcopenia is a progressive skeletal muscle disorder that contributes to disability, chronic disease burden, and mortality. While the roles of metabolic, cardiovascular, and kidney dysfunction are individually recognized, the collective influence of cardiovascular-kidney-metabolic (CKM) syndrome on sarcopenia remains uncharacterized. Furthermore, it is unclear whether physical inactivity amplifies this risk. This study is the first to apply the recently defined CKM staging framework to investigate sarcopenia risk, thereby offering an integrated, multisystem perspective.MethodsA cross-sectional analysis was conducted using 4,193 adults from the National Health and Nutrition Examination Survey 2011–2018 dataset. Sarcopenia was defined using the Foundation for the National Institutes of Health criteria. CKM syndrome was classified into five progressive stages (0–4), and physical activity was quantified using metabolic equivalent of task scores. Multivariable logistic regression models assessed the independent and combined associations of CKM stage and physical inactivity with sarcopenia, adjusting for demographic and clinical confounders. Subgroup and interaction analyses explored effect modification.ResultsThe overall prevalence of sarcopenia was 7.2%. Sarcopenia prevalence increased progressively across CKM stages, with the highest risk in advanced stages. CKM Stage 2 (OR = 1.58, 95% CI: 1.03–2.43, p = 0.037) and Stages 3–4 (OR = 3.51, 95% CI: 1.54–8.01, p = 0.003; p for trend < 0.001) were independently associated with sarcopenia. Physical inactivity further elevated sarcopenia risk (OR = 2.16, 95% CI: 1.56-3.00, p < 0.001). Joint analysis revealed a striking synergistic effect: individuals who were both physically inactive and in CKM Stages 3–4 had over sevenfold greater odds of sarcopenia compared to active individuals in Stage 0–1 (OR = 7.62, 95% CI: 3.02–19.21; p for trend < 0.001). Marital status significantly modified these associations (p for interaction = 0.038).ConclusionsThis study provides the first evidence linking CKM syndrome stages with sarcopenia risk and identifies a potent interaction with physical inactivity. These findings advance the conceptualization of sarcopenia as a multisystem disorder and underscore the importance of integrated lifestyle and disease management strategies to mitigate muscle loss in vulnerable populations.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12889-025-25740-3.Keywords: Sarcopenia, Cardiovascular-kidney-metabolic syndrome, Physical inactivity, NHANES, Synergistic risk Introduction Sarcopenia is a progressive and generalized skeletal muscle disorder characterized by the loss of muscle mass, strength, and physical performance [1, 2]. Although it is most commonly associated with aging, emerging evidence suggests that sarcopenia can also develop in midlife and in the context of chronic disease, contributing to functional decline and increased mortality across age groups [1–3]. Globally, sarcopenia affects approximately 10–16% of the elderly population and imposes a substantial economic burden on healthcare systems [3]. In the United States alone, sarcopenia was estimated to account for $18.5 billion in direct healthcare costs as early as 2000, with a 10% reduction in prevalence potentially saving over $1.1 billion annually [4]. These figures underscore the urgent need for early identification of high-risk individuals and implementation of targeted prevention strategies. Sarcopenia arises from a complex interplay of biological, behavioral, and clinical factors. In addition to well-established non-modifiable risk factors such as older age, lower body mass index, and female sex [5, 6], modifiable factors like physical inactivity, poor diet, smoking, and chronic diseases contribute significantly to its development [6–8]. Among these, physical inactivity is a consistently identified risk factor, with robust evidence linking it to loss of muscle strength and physical function [9]. Sarcopenia is also commonly observed in individuals with chronic conditions, including type 2 diabetes [6, 10], cardiovascular disease (CVD) [11], chronic kidney disease (CKD) [12], chronic obstructive pulmonary disease [13], and metabolic syndrome [14]. These conditions share overlapping mechanisms such as systemic inflammation, insulin resistance, oxidative stress, and hormonal dysregulation, all of which accelerate muscle degradation [15]. Despite this knowledge, most studies to date have examined the impact of individual diseases on sarcopenia in isolation. However, in clinical practice, multimorbidity is the norm rather than the exception. The cumulative burden of metabolic, cardiovascular, and renal dysfunction may synergistically exacerbate muscle decline, but this has not been systematically quantified. To address this gap, the American Heart Association recently introduced the concept of cardiovascular-kidney-metabolic (CKM) syndrome, a unified framework that integrates metabolic dysregulation, renal impairment, and cardiovascular risk along a continuum of disease progression [16]. CKM staging, ranging from Stage 0 (optimal cardiometabolic health) to Stage 4 (established clinical CVD), enables more comprehensive risk stratification and has shown strong predictive value for adverse outcomes such as cardiovascular events [17] and all-cause mortality [18]. However, to date, the association between CKM syndrome and sarcopenia has not been explored. Moreover, whether physical activity (PA) may mitigate the sarcopenia risk associated with advanced CKM stages is unknown. Understanding this relationship is critical, as it may reveal novel opportunities for intervention in populations with high cardiometabolic burden. Therefore, this study aims to investigate the independent and joint associations of CKM syndrome stages and physical inactivity with sarcopenia risk using data from the U.S. National Health and Nutrition Examination Survey (NHANES) 2011–2018 survey. By applying the CKM framework to sarcopenia for the first time, this study provides novel insight into the systemic nature of muscle loss and identifies high-risk groups who may benefit most from targeted lifestyle and clinical interventions. Our findings aim to inform the development of integrated preventive strategies in cardiology, nephrology, and metabolic care. Methods The data used in this study are openly available from the Centers for Disease Control and Prevention at https://www.cdc.gov/nchs/nhanes/index.html. Data source This cross-sectional study utilized data from the 2011–2018 cycles of the NHANES, a nationally representative survey conducted by the Centers for Disease Control and Prevention (CDC) using a stratified, multistage probability sampling design. NHANES collects detailed demographic, clinical, behavioral, dietary, and laboratory data from the non-institutionalized U.S. population. Written informed consent was obtained from all participants, and the survey protocol was approved by the National Center for Health Statistics Research Ethics Review Board [19]. All data used in this study are publicly available at https://www.cdc.gov/nchs/nhanes/index.html. This study adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Study population A total of 39,156 individuals participated in NHANES during the 2011–2018 cycles. We included adults aged ≥ 18 years and excluded pregnant women and those missing key demographic or clinical covariates, resulting in 17,332 eligible participants. We then excluded individuals lacking sufficient data to define CKM syndrome stages (n = 9,502) or those without valid information for sarcopenia (n = 3,637), yielding a final analytic sample of 4,193 participants (Fig. 1). This approach allowed us to generate a representative subsample of U.S. adults with sufficient data to operationalize the novel CKM syndrome framework in relation to sarcopenia risk. Working flowchart of participants inclusion and exclusion from NHANES 2011–2018. NHANES, National Health and Nutrition Examination Survey; CKM, cardiovascular-kidney-metabolic syndrome Definition of sarcopenia Sarcopenia was defined using criteria from the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project, which accounts for lean muscle mass relative to body size [20]. Specifically, sarcopenia was defined as an appendicular skeletal muscle mass (ASM) to body mass index (BMI) ratio < 0.789 for men and < 0.512 for women. ASM was measured via dual-energy X-ray absorptiometry (DXA), which estimates lean soft tissue mass in the limbs. This definition enables consistent, population-based identification of low muscle mass and has been widely applied in epidemiologic studies. Cardiovascular-kidney-metabolic (CKM) syndrome staging CKM syndrome stages were defined according to the 2023 American Heart Association scientific statement [21], adapted to align with available NHANES variables using the operationalization proposed by Aggarwal et al. (Supplementary Table S1) [22]. Participants were classified into five mutually exclusive CKM stages, reflecting increasing severity of metabolic, renal, and cardiovascular dysfunction: Stage 0: Optimal cardiometabolic health; Stage 1: Isolated adiposity-related risk; Stage 2: Presence of metabolic risk factors or moderate-to-high-risk CKD (as per Kidney Disease: Improving Global Outcomes guidelines) [23]; Stage 3: Subclinical CVD, defined as very high-risk CKD or a predicted 10-year CVD risk ≥ 20% (using the American Heart Association’s PREVENT equations) [24]; Stage 4: Established clinical CVD. Kidney function was assessed using the 2021 CKD-EPI creatinine equation without race adjustment [25], and albuminuria was evaluated via urinary albumin-to-creatinine ratio (UACR). This study is among the first to apply the CKM staging framework to sarcopenia risk, offering an integrative approach to capture systemic dysfunction. Physical activity (PA) assessment PA was assessed using the Global Physical Activity Questionnaire, developed by the World Health Organization (WHO) [26], which captures PA across work, transport, and leisure-time domains. Activities were categorized by intensity (moderate or vigorous), and total PA was quantified as weekly metabolic equivalent task minutes (MET-min/week) using the formula [27]: Standard MET values were applied (4.0 METs for moderate/transport activity, 8.0 METs for vigorous activity). Participants were classified into two categories: Inactive: < 600 MET-min/week; Active: ≥ 600 MET-min/week. This threshold reflects current WHO and CDC guidelines for recommended PA levels and has demonstrated strong predictive validity for major health outcomes [27]. Covariates We included a comprehensive set of covariates based on prior literature and clinical relevance. These included: Demographic factors: age (continuous), sex (male/female), race/ethnicity (non-Hispanic White, non-Hispanic Black, Asian, Mexican American, Hispanic); Socioeconomic status: education level, marital status, family income-to-poverty ratio (< 1.30, 1.30–3.49, >3.49); Health-related behaviors and conditions: BMI (continuous), smoking status, alcohol use, sleep duration (< 7, 7–8, >8 h), and hypertension diagnosis. All covariates were collected via standardized NHANES protocols and questionnaires. Statistical analysis All statistical analyses were performed using R version 4.3.2 and incorporated NHANES complex survey design, including strata, primary sampling units, and sample weights. Descriptive analyses compared participant characteristics by sarcopenia status using weighted t-tests or Wilcoxon rank-sum tests for continuous variables and chi-square tests for categorical variables. Multivariable logistic regression models were constructed to evaluate the independent associations of PA status and CKM stages with sarcopenia: Model 1: Adjusted for demographic variables (age, sex, ethnicity, education, marital status, income); Model 2: Further adjusted for health-related factors (BMI, hypertension, sleep, smoking, alcohol). A linear trend test was conducted across CKM stages. Subgroup analyses were conducted stratified by age, sex, race/ethnicity, marital status, education, income, smoking, drinking, hypertension, and PA. Interaction terms were tested to assess potential effect modification. Joint exposure analysis examined the combined effects of PA and CKM stage using a 6-level cross-classified variable (Active/Inactive × CKM Stages 0–1, 2, 3–4). “Active with CKM 0–1” served as the reference group. A two-tailed p-value < 0.05 was considered statistically significant. Results Participant characteristics A total of 4,193 adult participants were included in the final analytic sample from NHANES 2011–2018. The mean age was 39 years, and 50.2% were female. The overall prevalence of sarcopenia was 7.2%. Table 1 summarizes baseline characteristics stratified by sarcopenia status. Participants with sarcopenia were significantly older (mean: 43 vs. 39 years, p < 0.001) and had higher BMI (mean: 35 vs. 28 kg/m², p < 0.001) than those without sarcopenia. The sarcopenia group also had greater representation among Mexican American and Hispanic individuals (24% and 13%, respectively) and reported lower levels of education and income. Health-related disparities were prominent: the sarcopenia group had a higher prevalence of hypertension (35% vs. 22%) and physical inactivity (47% vs. 29%), and significantly lower mean MET scores (5,154 ± 8,554 vs. 7,454 ± 27,253, p < 0.001). Table 1Baseline characteristics of participants by sarcopenia statusCharacteristicsTotalNormalSarcopeniaP valueWeighted cases114,289,849 (100%)106,059,642 (93%)8,230,207 (7.2%)Age, mean ± SD39 ± 1239 ± 1243 ± 11< 0.001Sex0.2 Female2104 (50%)1920 (50%)184 (45%) Male2089 (50%)1903 (50%)186 (55%)BMI (kg/m2), mean ±SD29 ± 728 ± 635 ± 8< 0.001Ethnicity< 0.001 White1567 (37.4%)1450 (37.9%)117 (31.6%) Black830 (19.8%)810 (21.2%)20 (5.4%) Asian585 (5.5%)537 (14%)48 (13%) Mexican611 (14%)496 (13%)115 (31.1%) Hispanic426 (10.2%)367 (9.6%)59 (15.9%) Other multi-racial174 (4.1%)163 (4.3%)11 (3%)Education level< 0.001 College above1200 (33%)1133 (34%)67 (21%) Some college1362 (33%)1259 (33%)103 (31%) High school1631 (34%)1431 (33%)200 (48%)Marital status0.8 Married/Living with partner2480 (62%)2245 (62%)235 (63%) Widowed/Divorced/Separated585 (13%)526 (13%)59 (13%) Never married1128 (25%)1052 (25%)76 (24%)Family income index< 0.001 >3.491280 (40%)1197 (41%)83 (26%) 1.30–3.491531 (36%)1403 (36%)128 (37%) <1.301382 (24%)1223 (23%)159 (37%)Sleep duration0.006 <7 h2412 (56%)2221 (56%)191 (49%) 7–8 h1162 (29%)1054 (29%)108 (30%) >8 h619 (15%)548 (14%)71 (22%)Hypertension< 0.001 Yes1000 (23%)875 (22%)125 (35%) No3193 (77%)2948 (78%)245 (65%)Smoking status0.9 Yes1709 (42%)1558 (42%)151 (42%) No2484 (58%)2265 (58%)219 (58%)Drinking status< 0.001 Yes3342 (84%)3072 (85%)270 (75%) No851 (16%)751 (15%)100 (25%)MET score, mean ± SD7,288 ± 26,3607,454 ± 27,2535,154 ± 8,554< 0.001 Active physical activity2835 (70%)2639 (71%)196 (53%) Inactive physical activity1358 (30%)1184 (29%)174 (47%)CKM Stage< 0.001 Stage 0463 (12%)460 (13%)3 (1%) Stage 1951 (23%)880 (23%)71 (20%) Stage 22521 (60%)2274 (60%)247 (66%) Stage 398 (2%)79 (1%)19 (5%) Stage 4160 (2%)130 (3%)30 (8%)Abbreviations BMI body mass index, CKM cardiovascular-kidney-metabolic syndrome, Met score metabolic equivalent of task score. Data are presented as weighted counts (weighted %), means ± SD, or counts (proportions) as appropriate. P values were calculated using weighted chi-square tests for categorical variables and weighted t-tests for continuous variables Baseline characteristics of participants by sarcopenia status Abbreviations BMI body mass index, CKM cardiovascular-kidney-metabolic syndrome, Met score metabolic equivalent of task score. Data are presented as weighted counts (weighted %), means ± SD, or counts (proportions) as appropriate. P values were calculated using weighted chi-square tests for categorical variables and weighted t-tests for continuous variables Distribution of CKM syndrome stages by sarcopenia status Figure 2 and Table 1 display the distribution of CKM stages in the full cohort and by sarcopenia status. In the total sample, the majority of participants were in CKM Stage 2 (60%), followed by Stage 1 (23%), Stage 0 (12%), and Stages 3 and 4 (2% each). This pattern persisted in the non-sarcopenia group. In contrast, individuals with sarcopenia were disproportionately concentrated in advanced CKM stages. Specifically, only 1% were in CKM Stage 0, while 5% and 8% were in Stages 3 and 4, respectively—compared to 1% and 3% in the non-sarcopenia group. This distribution reveals a clear shift toward more severe multisystem dysfunction among those with sarcopenia. Proportional distribution of CKM stages in the total sample by sarcopenia status. Red bars indicate the weighted proportion of the overall population in each CKM stage; dark blue bars represent the distribution of CKM stages among individuals without sarcopenia; light blue bars represent the distribution of CKM stages among individuals with sarcopenia. CKM, cardiovascular-kidney-metabolic syndrome Independent associations of PA and CKM stage with sarcopenia Multivariable logistic regression analyses (Table 2) demonstrated that both physical inactivity and advancing CKM stage were independently associated with higher odds of sarcopenia. Inactive individuals had more than twice the odds of sarcopenia compared to their active counterparts (Model 2: OR = 2.16; 95% CI: 1.56–3.00; p < 0.001). A clear dose-response relationship with the odds of sarcopenia was observed for CKM syndrome stage: Stage 2 vs. Stage 0–1: OR = 1.58 (95% CI: 1.03–2.43; p = 0.037); Stages 3–4 vs. Stage 0–1: OR = 3.51 (95% CI: 1.54–8.01; p = 0.003). The trend across all CKM stages was statistically significant (p for trend < 0.001), indicating a progressive increase in sarcopenia risk with worsening multisystem dysfunction. Notably, these findings establish, for the first time, that CKM syndrome staging—a framework originally proposed to predict cardiovascular and renal outcomes—is also a strong predictor of sarcopenia risk. Table 2Associations of physical activity levels and CKM stage with sarcopeniaCharacteristicsWeighted CaseRate (%)Crude ModelModel 1Model 2OR 95% CIP valueOR 95% CIP valueOR 95% CIP valueMet Score Active physical activity53ReferenceReferenceReference Inactive physical activity472.21 (1.65–2.96)< 0.0012.21 (1.59–3.08)< 0.0012.16 (1.56–3.00)< 0.001CKM Stage Stage 0–121ReferenceReferenceReference Stage 2661.86 (1.28–2.72)0.0011.74 (1.16–2.62)0.0081.58 (1.03–2.43)0.037 Stage 3–4135.07 (2.73–9.40)< 0.0014.06 (1.94–8.51)< 0.0013.51 (1.54–8.01)0.003 P for trend< 0.001< 0.001< 0.001Abbreviations CKM cardiovascular-kidney-metabolic syndrome, OR odds ratio, CI confidence interval. ORs and 95% CIs were calculated using logistic regression. The crude model was unadjusted. Model 1 was adjusted for age, sex, ethnicity, educational level, marital status, and family income index. Model 2 was further adjusted for hypertension, sleep duration, smoking status, and alcohol status. Active physical activity and CKM stages 0–1 were used as reference groups for physical activity and CKM stage analyses respectively Associations of physical activity levels and CKM stage with sarcopenia Abbreviations CKM cardiovascular-kidney-metabolic syndrome, OR odds ratio, CI confidence interval. ORs and 95% CIs were calculated using logistic regression. The crude model was unadjusted. Model 1 was adjusted for age, sex, ethnicity, educational level, marital status, and family income index. Model 2 was further adjusted for hypertension, sleep duration, smoking status, and alcohol status. Active physical activity and CKM stages 0–1 were used as reference groups for physical activity and CKM stage analyses respectively Subgroup and interaction analyses Subgroup analyses (Fig. 3) showed that the association between higher CKM stages and sarcopenia was generally consistent across sex, age, ethnicity, education, income, smoking, drinking, and hypertension subgroups. Most interaction terms were not statistically significant (p > 0.05), suggesting robustness of the CKM–sarcopenia link across diverse populations. However, marital status significantly modified the association (p for interaction = 0.038). Among never-married individuals, the odds of sarcopenia were markedly elevated (OR = 2.00; 95% CI: 1.49–2.68), compared to married/partnered individuals (OR = 1.47) or those widowed/divorced/separated (OR = 1.30). There was also a trend toward interaction with education level (p = 0.065) and hypertension (p = 0.092), suggesting that socioeconomic context and comorbidities may modulate vulnerability to sarcopenia in the presence of multisystem dysfunction. Forest plot of subgroup analysis for the association between CKM stage and risk of sarcopenia. The figure displays ORs and their 95% CIs for each subgroup. Each square represents the OR value with horizontal line indicating the 95% CI. The P values for interaction were used to assess heterogeneity of effects across subgroups. CKM, cardiovascular-kidney-metabolic syndrome; OR, odds ratio; CI, confidence interval Joint association of PA and CKM syndrome stage with sarcopenia Joint analyses revealed a synergistic effect between physical inactivity and CKM progression (Table 3; Fig. 4). As shown in Table 3, in Model 2 of the logistic regression analyses, physically inactive individuals exhibited significantly higher odds of sarcopenia compared to their active counterparts within both CKM stage 0–1 (OR = 3.53; 95% CI: 1.76–7.09) and CKM stage 2 (OR = 1.86; 95% CI: 1.30–2.67). A significant multiplicative interaction was observed between PA and CKM stages (p for interaction < 0.001), indicating the adverse effect of inactivity on muscle health intensifies with advancing multisystem burden. Table 3Associations between physical activity levels and sarcopenia stratified by CKM stageCharacteristicsWeightedRate (%)Crude ModelModel 1Model 2OR 95% CIP valueOR 95% CIP valueOR 95% CIP valueCKM Stage 0–1 Active physical activity101 [Reference]1 [Reference]1 [Reference] Inactive physical activity123.29 (1.64–6.62)< 0.0013.58 (1.77–7.23)< 0.0013.53 (1.76–7.09)< 0.001CKM Stage 2 Active physical activity361 [Reference]1 [Reference]1 [Reference] Inactive physical activity301.94 (1.45–2.60)< 0.0011.91 (1.33–2.75)< 0.0011.86 (1.30–2.67)< 0.001CKM Stage 3–4 Active physical activity71 [Reference]1 [Reference]1 [Reference] Inactive physical activity61.42 (0.69–2.94)0.0351.02 (0.30–3.39)0.981.15 (0.41–3.23)0.80Abbreviations CKM cardiovascular-kidney-metabolic syndrome, OR odds ratio, CI confidence interval. ORs and 95% CIs were calculated using logistic regression. The crude model was unadjusted. Model 1 was adjusted for age, sex, ethnicity, educational level, marry status, and family income index. Model 2 was further adjusted for hypertension, sleep duration, smoking status, and alcohol status Associations between physical activity levels and sarcopenia stratified by CKM stage Abbreviations CKM cardiovascular-kidney-metabolic syndrome, OR odds ratio, CI confidence interval. ORs and 95% CIs were calculated using logistic regression. The crude model was unadjusted. Model 1 was adjusted for age, sex, ethnicity, educational level, marry status, and family income index. Model 2 was further adjusted for hypertension, sleep duration, smoking status, and alcohol status Forest plot of the joint analysis of physical activity levels and CKM stages with sarcopenia risk. The figure illustrates the impact of insufficient physical activity on the risk of sarcopenia, stratified by CKM stage. Each square represents the OR value, and the horizontal line indicates the 95% CI. CKM, cardiovascular-kidney-metabolic syndrome; OR, odds ratio; CI, confidence interval Although the association among inactive individuals in CKM stages 3–4 did not reach statistical significance, likely due to a smaller sample size in this subgroup, further analysis using a combined exposure variables provided a clearer picture. As shown in Fig. 4, participants were categorized into six joint exposure groups (Active/Inactive × CKM Stages 0–1, 2, 3–4). Compared with the reference group—active individuals in CKM Stage 0–1—the odds of sarcopenia increased substantially across the following joint categories: Inactive + Stage 0–1: OR = 3.53 (95% CI: 1.76–7.09); Inactive + Stage 2: OR = 3.87 (95% CI: 2.16–6.92); Inactive + Stages 3–4: OR = 7.62 (95% CI: 3.02–19.21). The trend across all joint exposure groups statistically significant (p for trend < 0.001), and physically inactive individuals with CKM stages 3–4 had the highest risk of sarcopenia. These findings demonstrate that physical inactivity magnifies the impact of CKM progression on sarcopenia risk, supporting a synergistic impact of inactivity and advanced multisystem dysfunction. Notably, even among individuals with elevated CKM burden, those who remained physically active had significantly lower odds of sarcopenia: Active + Stage 2: OR = 2.08 (95% CI: 1.23–3.54); Active + Stages 3–4: OR = 4.89 (95% CI: 1.84–12.98). These findings suggest that PA may partially offset the detrimental effects of advanced CKM burden on muscle health. Discussion In this nationally representative sample of U.S. adults, we found that both CKM syndrome and physical inactivity were independently and jointly associated with an elevated risk of sarcopenia. The highest odds of sarcopenia were observed in individuals with both physical inactivity and advanced CKM stages (OR = 7.62), suggesting a synergistic interaction between systemic cardiometabolic dysfunction and modifiable lifestyle risk. These associations remained robust across multiple demographic and clinical subgroups after rigorous adjustment for potential confounders. To our knowledge, this is the first study to apply the American Heart Association’s CKM syndrome staging framework to sarcopenia. This novel systems-based approach moves beyond traditional single-disease models and offers an integrated lens through which to view sarcopenia as a multisystem consequence of cardiometabolic and renal deterioration. Our findings extend prior evidence linking sarcopenia to individual chronic conditions—such as diabetes, CKD, and CVD—by demonstrating a graded, dose-dependent increase in sarcopenia risk across CKM stages [28, 29]. These results reinforce the concept of sarcopenia as a downstream manifestation of cumulative physiological burden and chronic low-grade inflammation [30, 31]. Several biological mechanisms may underlie this observed association. CKM syndrome is characterized by insulin resistance, mitochondrial dysfunction, systemic inflammation, and hormonal imbalances, all of which promote muscle catabolism and impair muscle protein synthesis [17, 32, 33]. Elevated levels of tumor necrosis factor-α, interleukin-6, and C-reactive protein—commonly found in patients with advanced CKM—have been shown to accelerate muscle degradation and reduce regenerative capacity [34, 35]. Additionally, physical inactivity may exacerbate these effects by diminishing neuromuscular stimulation, lowering anabolic signaling, and promoting adipose infiltration of muscle tissue [36, 37]. Importantly, our joint exposure analysis highlights a clinically meaningful interaction: while CKM burden significantly increased the odds of sarcopenia, physically active individuals in advanced CKM stages had substantially lower sarcopenia risk compared to their inactive counterparts. This suggests that PA may buffer or attenuate the adverse muscle effects of systemic metabolic and vascular dysfunction, offering a compelling rationale for integrating exercise into multidisciplinary care models for at-risk populations [6, 38]. Although sarcopenia is often regarded as an age-related [39], our relatively young cohort (mean age: 39 years) and other existing evidence suggest that secondary sarcopenia can also emerge earlier in life due to modifiable risk factors such as metabolic syndrome, physical inactivity, and chronic disease burden [40], reinforcing the need for risk-based, rather than age-based, screening and prevention strategies. Marital status emerged as a significant effect modifier in our study, suggesting that social and emotional support may buffer the adverse impact of multisystem metabolic stress on muscle health. Unmarried individuals often exhibit lower PA levels, poorer diet quality, and higher rates of depressive symptoms, which together may accelerate muscle loss. Clinically, this finding underscores the importance of incorporating social and behavioral factors into sarcopenia prevention strategies and highlights the potential value of integrating social support assessment and family-centered approaches into CKM management, while from a societal perspective, it highlights the value of strengthening social support networks and community engagement in reducing sarcopenia risk among metabolically vulnerable individuals [41–43]. Taken together, these findings underscore the potential of lifestyle modification to mitigate muscle decline in at-risk populations and warrant further exploration into the role of social support, loneliness, and behavioral health in the development of sarcopenia. Key strengths of our study include the use of a large, nationally representative dataset with standardized assessments, detailed staging of CKM syndrome, and comprehensive covariate adjustment. The application of the CKM framework to sarcopenia represents an important methodological innovation with potential to inform risk stratification, prevention, and treatment strategies in clinical practice. Nonetheless, several limitations merit consideration. First, the cross-sectional design precludes causal inference. It remains unclear whether CKM burden and inactivity precede sarcopenia or whether sarcopenia contributes to reduced activity and worsening systemic health—a likely bidirectional relationship. Longitudinal and interventional studies are needed to clarify temporal pathways. Second, our operational definition of sarcopenia relied on low lean mass measured by DXA, without incorporating functional measures such as grip strength or gait speed, potentially underestimating true prevalence. Third, NHANES does not include institutionalized populations, which may limit generalizability to older or more frail individuals [3, 40]. Fourth, because individuals with incomplete data on CKM staging or comorbidities were excluded, the analytic sample may represent a relatively healthier subset of the NHANES population. This selection could lead to underestimation of sarcopenia prevalence and attenuate the observed associations. Fifth, while our analyses adjusted for socioeconomic factors such as education and income, these variables may not fully capture the multidimensional nature of social support. Future studies should integrate broader indicators of social connectedness—such as household composition, community involvement, and perceived social isolation—to better elucidate how social networks influence sarcopenia risk among individuals with advanced CKM burden [42]. Finally, self-reported PA is subject to recall and reporting biases. Despite these limitations, our study provides new insights into the systemic nature of sarcopenia and identifies a high-risk group—physically inactive individuals with advanced CKM burden—that may benefit from early intervention. Conclusions In conclusion, this study is the first to demonstrate that both CKM syndrome stages and physical inactivity are independent and synergistic risk factors for sarcopenia in a general adult population. The risk of sarcopenia increases in a dose-dependent manner across CKM stages and is markedly elevated in individuals with coexisting physical inactivity. These findings underscore the value of integrated risk frameworks such as CKM staging for identifying individuals at heightened vulnerability to muscle loss. Our results highlight the importance of screening for muscle health in the management of cardiometabolic and renal disease and point to PA as a promising modifiable target to mitigate sarcopenia risk. Future longitudinal and interventional studies are warranted to establish causality and test tailored prevention strategies in individuals with high CKM burden. Supplementary Information Supplementary Material 1 Acknowledgements The authors are grateful to the members and participants of the NHANES. Authors’ contributions Yifeng Luo, Wei Chen, and Bin Li have full access to all the data in this study and assumes responsibility for study supervision. Dingding Wang, Meng Zhang, Qinghua Fan, and Bin Li conceived and designed the study; Dingding Wang, Meng Zhang, Qinghua Fan, Jianwen Yu, Jianbo Li, Lanping Jiang, Xunhua Zheng, Siyang Ye, Suchun Li, Peichen Xie, Li Tan, Sixiu Chen, and Weixuan Qin analyzed the data; Dingding Wang, Meng Zhang, Qinghua Fan, and Bin Li drafted the original manuscript and created the figures; Leigang Jin and Xiaoping Wu helped data collection, and provided technical or material support; Sydney C.W. Tang, Yifeng Luo, and Wei Chen reviewed and edited the writing. All authors approved the final version of the manuscript. Funding This work was supported by Natural Science Foundation of Guangdong Province (No. 2024A1515013210, 2024A1515012914), National Natural Science Foundation of China (82200803), Guangzhou Science and Technology Project (2025A04J4173), National Key Research and Development Project of China (No. 2021YFC2501302), NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University), Guangdong Provincial Key Laboratory of Nephrology, Guangdong International Science and Technology Cooperation Institute of Immune Kidney Disease and Precision Medicine, General Project of Natural Science Foundation of Guangdong Province (No. 2019A1515010992), and Guangdong Medical Science and Technology Research Fund Project of China (No. A2020085). Data availability The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found at: https://www.cdc.gov/nchs/nhanes/index.html. Declarations Ethics approval and consent to participate Data collection for the NHANES was approved by the NCHS Research Ethics Review Board (ERB). An individual investigation utilizing the publicly available NHANES data do not need to file the institution internal review board (IRB). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Dingding Wang, Meng Zhang and Qinghua Fan contributed equally to this work. Contributor Information Yifeng Luo, Email: lyif@mail.sysu.edu.cn. Wei Chen, Email: chenwei99@mail.sysu.edu.cn. Bin Li, Email: libin55@mail2.sysu.edu.cn. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found at: https://www.cdc.gov/nchs/nhanes/index.html.